VolitionRX (VNRX)
:VNRX
Want to see VNRX full AI Analyst Report?
Earnings Data
Report Date
May 13, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
―Last Year’s EPS
-0.06Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed substantial scientific and commercial progress across multiple pillars—CE‑marked product revenue, government‑backed interventional study inclusion, a >99% pure ctDNA Capture‑Seq breakthrough, new partner agreements, veterinary automation advances, and multiple peer‑reviewed publications. At the same time, the company remains in early commercialization with a small absolute revenue base ($1.7M), lumpy revenues, significant cash burn ($19.7M net cash used) and a low year‑end cash balance partially addressed by subsequent financings. Scaling depends on successful licensing, reimbursement (notably France expected Q4 2026) and larger validation studies. On balance, the call emphasized transformative technology and clear commercialization traction while acknowledging near‑term execution and funding risks.Company Guidance
Strong Revenue Growth in 2025
Full year 2025 revenue of $1.7M, up 40% year‑over‑year; Q4 2025 year‑over‑year growth of 133%. First revenue recognized from CE‑marked Nu.Q NETs product in Europe.
Operating Cost Reductions and Improved Cash Burn
Operating expenses reduced by $4.8M (17% decline vs. 2024). Net cash used in operating activities fell to $19.7M (down 24% YoY from $25.9M). Management is targeting a further 25%–30% reduction in cash OpEx during 2026.
Post‑Year‑End Financing Bolsters Liquidity
Cash and cash equivalents were ~$1.1M at year‑end; subsequent net proceeds through March 25 included ~$5.4M from the ATM facility and $1.9M from a convertible note. Additional nondilutive funding of ~$2.3M was announced, taking total nondilutive funding from inception to date to >$25M.
Government‑Backed Real‑World Program for Sepsis (DETECSEPS)
Nu.Q NETs (H3.1) included as sole biomarker in the DETECSEPS real‑world interventional early sepsis detection program backed by the French government (~$7.3M program), moving the test into interventional clinical use.
Clinical and Peer‑Reviewed Validation Momentum
Multiple peer‑reviewed and independent clinical studies published/announced: large studies with UMC Amsterdam (>1,700 ICU patients) and Jena (971 patients) showing H3.1 discriminates sepsis vs noninfectious inflammation and provides prognostic power exceeding APACHE II and SOFA; Mayo Clinic publication (674 trauma patients) showing elevated nucleosome levels predict complications.
Nu.Q Capture‑Seq Scientific Breakthrough
Capture‑Seq produced >99% pure circulating tumor DNA sequencing sets. Blinded validation cohort (81 subjects: 59 colorectal/lung cancer, 22 controls) detected >95% of Stage 1 and 2 cancers in the study, indicating strong early‑stage detection potential and generating significant partner interest.
Commercial & Partnership Progress Across Pillars
Signed human licensing/co‑marketing agreements (e.g., Werfen for APS/NETs; Hologic co‑marketing; Revvity/PerkinElmer CE‑marked kit); Nu.Q Discover now serving ~100 clients, including top pharma/diagnostics; first pharma sponsor using Nu.Q Discover biomarkers in a longitudinal Phase I/IIb study. Management reports active discussions with ~10 leading diagnostic/liquid biopsy companies.
Veterinary Market Leadership and Automation Milestones
Nu.Q Vet Cancer Test is the #1 canine cancer screening blood test in >20 countries. Fujifilm Vet Systems extended contract to implement centralized automated platform; ChLIA (chemiluminescent immunoassay) validation completed with Fuji Vet Systems in Japan enabling full automation and higher throughput.
Feline Assay Breakthrough and Milestone Trigger
Clinical study showed Nu.Q Vet feline assay detected >80% of feline lymphomas at 100% specificity. Peer‑reviewed publication is expected to unlock a $5M milestone payment and enable entrance into a large U.S. cat population market opportunity.
Point‑of‑Care Lateral Flow Development
Demonstrated lateral flow quantification of nucleosomes in whole blood in minutes; second phase research underway comparing whole blood and capillary blood in critically ill patients—potential for low‑resource/POC deployment.
VNRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
VNRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 31, 2026 | $0.20 | $0.20 | -0.99% |
Nov 13, 2025 | $0.35 | $0.33 | -6.50% |
Aug 14, 2025 | $0.64 | $0.69 | +7.93% |
May 15, 2025 | $0.45 | $0.43 | -5.30% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does VolitionRX (VNRX) report earnings?
VolitionRX (VNRX) is schdueled to report earning on May 13, 2026, After Close (Confirmed).
What is VolitionRX (VNRX) earnings time?
VolitionRX (VNRX) earnings time is at May 13, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VNRX EPS forecast?
Currently, no data Available